Véronique Debien, Medical Oncologist at Institute Bergonié, shared a post on LinkedIn:
“At ESMOTAT26 this week in Paris, an important point on ADC development by Raffaele Colombo and Dr Barbara Pistilli:
Pharmacokinetics is central to understanding and anticipating its toxicity.
As the field matures, toxicity is not only a function of target or payload, but also of exposure and its variability.
This raises important implications for drug development:
- Need for PK-informed dose and schedule optimization
- Better integration of PK with clinical and biological data
- Potential for predictive models of ADC-related toxicities
The challenge is clear: maintain efficacy while anticipating and better managing toxicity, moving from empirical toxicity management to anticipation and prediction.
A timely reminder that optimizing ADCs will not only rely on better molecules, but also on a deeper understanding of how they behave in patients.”
Other articles featuring Véronique Debien on OncoDaily.
